Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.
Miromatrix Medical Inc. (symbol: MIRO) is an innovative life sciences company focused on developing bioengineered organs for transplantation. The company leverages its proprietary technology to decellularize organs and tissues from both animal and human sources, creating a platform for producing fully transplantable human organs. This cutting-edge technology aims to address the critical shortage of donor organs, potentially saving and improving countless lives.
Miromatrix has garnered significant recognition for its pioneering work. The company's CEO, Dr. Jeff Ross, recently presented their advancements in kidney bioengineering at the American Transplant Congress (ATC), where they received the prestigious Best in Congress acknowledgment. Additionally, Miromatrix's Medical Director, Dr. Jack Lake, was honored with the American Society of Transplantation's 2023 Lifetime Achievement Award, the Society's highest honor, for his outstanding contributions to the field of transplantation.
The company's current focus is on the development of human livers and kidneys, utilizing its perfusion technology platform. This platform is designed to efficiently scale the bioengineering process, making it feasible to produce a larger number of transplantable organs. Miromatrix is actively involved in various research initiatives and collaborates with leading scientists such as David Lo to advance their technology further.
Financially, Miromatrix recently reported their second-quarter 2023 results, showcasing their progress and strategic direction. They continue to engage with investors and the media through scheduled presentations at significant events such as the ARM Tissue and Engineering and Therapeutics Workshop and the H.C. Wainwright Annual Global Investment Conference.
For the latest updates and detailed information on Miromatrix Medical Inc., including their recent achievements and ongoing projects, visit their official website at miromatrix.com.
Miromatrix Medical Inc. (NASDAQ: MIRO) reported its first quarter 2022 financial results, showing a cash balance of $44.7 million as of March 31, down from $52.8 million at year-end 2021. The company faced an operating and net loss of $7.2 million, significantly higher than $2.7 million and $0.4 million in Q1 2021, respectively, due to increased operational costs. However, Miromatrix is progressing towards human clinical trials, aiming to file an IND application for the MiroliverELAP™ product in H2 2022. Notably, the company announced the departure of VP Laji Kattungal for personal reasons.
Miromatrix Medical Inc. (NASDAQ: MIRO) will announce its first quarter 2022 financial results on May 16, 2022, after market close. A conference call is scheduled for the same day at 3:30 PM CT/4:30 PM ET. Miromatrix specializes in bioengineering transplantable organs using proprietary perfusion technology, focusing primarily on human livers and kidneys. The advancements aim to address the shortage of available human organs, potentially enhancing patient outcomes.
Miromatrix Medical Inc. (NASDAQ: MIRO), a leader in bioengineering transplantable organs, will have CEO Jeff Ross present at the 2022 Cell & Gene Meeting on the Mediterranean from April 20-22 in Barcelona, Spain. Ross's presentation is scheduled for April 21 at 3:45 pm CET and will be streamed live, followed by a Q&A session. He emphasized the transformative potential of their perfusion technology in addressing the shortage of human organs. The conference gathers industry leaders to discuss advancements in advanced therapies, with over 650 attendees expected.
Miromatrix Medical Inc. (NASDAQ: MIRO) reported its fourth quarter and full year 2021 financial results. The company ended 2021 with $52.8 million in cash, sufficient to support operations through 2023. Notably, it achieved significant milestones including the first successful transplant of a bioengineered organ in partnership with Mayo Clinic and plans for a phase 1 clinical trial of MiroliverELAP in 2022. However, the company reported a net loss of $14.7 million for the year, with total revenues of only $33,000.
Miromatrix Medical Inc. (NASDAQ: MIRO) has announced the relocation to a new 42,000 square foot headquarters in suburban Minneapolis, which includes a dedicated 11,000 square foot in-house manufacturing facility. This move aims to enhance production quality and development timelines as the company prepares for the first-ever in-human clinical trials for bioengineered organs. The facility is designed to support pre-clinical and clinical trial stages, maintaining standards similar to its previous ISO 13485 certified manufacturing site. An inauguration ceremony is scheduled for April 27, 2022.
Miromatrix Medical Inc. (NASDAQ: MIRO) will report its financial results for the fourth quarter and full year 2021 on March 30, 2022, after market close. The company specializes in pioneering bioengineering technology for transplantable human organs, focusing primarily on livers and kidneys. Following the report, a conference call will take place at 3:30 PM CT, where management will discuss the results. Interested parties can join the call or listen to a live webcast through the company's investor relations webpage.
Miromatrix Medical (NASDAQ: MIRO) announced its participation in CareDx's Xenotransplantation Innovation Day on March 22, 2022. This virtual event will showcase advancements in transplant technology, including updates on pioneering pig-to-human organ transplants. Miromatrix will discuss its bioengineering efforts aimed at creating human-compatible organs. CEO Jeff Ross emphasized the company’s commitment to addressing the organ transplant shortage and improving patient outcomes. Registration for the event is available online.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced the appointment of Jim Douglas as CFO effective March 1, 2022. Douglas brings over 25 years of experience in investment banking and finance, having worked at Piper Sandler and Abbott Laboratories. He succeeds Brian Niebur, who will transition to Vice President of Finance after significant contributions, including guidance during Miromatrix's IPO. The leadership change signals a strategic move as the company focuses on bioengineering transplantable organs, aiming to eliminate the transplant waitlist.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its plan to ring the Nasdaq closing bell on February 14, 2022, at 4:00 p.m. ET, in honor of National Donor Day and its public listing. CEO Jeff Ross will be joined by key investors, including Baxter, CareDx, and DaVita. Ross highlighted the company’s efforts in bioengineering transplantable organs and mentioned a recent pre-IND request to the FDA for a liver assist product aimed at treating acute liver failure. The event aims to celebrate the progress made in eliminating organ transplant waitlists.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022, at 2:00 PM ET. The company specializes in bioengineering fully transplantable organs, with a focus on addressing organ shortages through its proprietary perfusion technology platform. Miromatrix aims to help save lives by developing human livers and kidneys. Interested parties can listen to the live event by contacting their BTIG representative.
FAQ
What is the market cap of Miromatrix Medical (MIRO)?
What does Miromatrix Medical Inc. specialize in?
What recent recognition has Miromatrix received?
What are Miromatrix's primary focus areas?
What technology does Miromatrix use for bioengineering organs?
How is Miromatrix addressing the shortage of donor organs?
Who are some key figures in Miromatrix?
What events has Miromatrix recently participated in?
Where can I find more information about Miromatrix?
What recent financial results has Miromatrix reported?
Who can I contact for investor relations at Miromatrix?
